Ghariq, M.
van den Hout, W. B.
Dekkers, O. M.
Bootsma, M.
de Groot, B.
Groothuis, J. G. J.
Harms, M. P. M.
Hemels, M. E. W.
Kaal, E. C. A.
Koomen, E. M.
de Lange, F. J.
Peeters, S. Y. G.
van Rossum, I. A.
Rutten, J. H. W.
van Zwet, E. W.
van Dijk, J. G.
Thijs, R. D.
,
Tuinema, R. M.
Voet, W.
Boerman, D. B.
Firouzi, M.
Fokke, C.
Funding for this research was provided by:
ZonMw (843002707)
Article History
Received: 4 February 2023
Accepted: 29 August 2023
First Online: 25 September 2023
Declarations
:
: The study protocol was approved by the ethical committee of Leiden University Medical Centre (NL58852.058.16/ P16.228) and the review boards of each participating site. All participants gave their written informed consent.
: Not applicable.
: RDT receives research support from the Dutch National Epilepsy Fund, The Netherlands Organisation for Health Research and Development (ZonMW), Medtronic, Vriendenlotterij and the Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, The Netherlands. RDT and JR receive research support from Michael J Fox Foundation.MEWH received lecture fees from Medtronic. RDT received fees for lectures from Medtronic, UCB and Novartis; consultancy fees from Theravarance, Xenon, Angelini and Arvelle; and research support from New Life Wearables and Medtronic. All other authors declare that they have no competing interests.